Biobanking: Technologies and Global Markets
Report Highlights
The global market for biobanking is estimated to increase from $61.1 billion in 2021 to $76.2 billion by 2026, at a compound annual growth rate (CAGR) of 4.5% during 2021-2026.
Report Includes
- 22 data tables and 29 additional tables
- An up-to-date review and analysis of the global markets for biobanking technologies
- Analyses of the global market trends, with data from 2019-2021, and projections of compound annual growth rates (CAGRs) through 2026
- Highlights of the upcoming market potential for biobanking technologies, and areas of focus to forecast this market into various segments and sub-segments
- In-depth information (facts and figures) concerning market drivers, market deterrents and other demographic and economic factors that will drive future demand for biobanking products
- Evaluation and forecast the overall market size for biobanks, forecasted growth trends, and corresponding market share analysis by sample type, application, ownership type, and region
- Identification of novel biobanking products and promising new technologies still in the development and testing stage and assess the probability that they will be commercialized successfully in the next five years
- Review of emerging companies and the leading competitors in the prevailing biobanking industry
- Insight into recent patent activities on biobanking techniques, R&D activities, clinical trials under process, and selected list of biobanking studies
- Descriptive company profiles of the major global players, including Agilent Technologies Inc., AstraZeneca plc, Bruker Corp., Hamilton Co., Merck KGaA, Qiagen N.V., and Thermo Fisher Scientific Inc.
Report Scope
This report aims to provide a comprehensive study of the global market for biobanking. It provides a detailed description of the different types of biobanks (disease-oriented/clinical based and population-based) worldwide. The biobanking market is segmented based on their application as basic/scientific research and clinical research/therapeutics. Each application segments’ historical and projected market revenues are provided in the report. The global market for biobanking is also segmented based on sample type (as biofluids, tissue, stem cells, DNA/RNA and others) and ownership types (government agencies/public sector providers, academic institutes/universities, non-profit organizations and private organizations). The market revenue for each geographical segment, including North America, Europe, Asia-Pacific and Rest of the World (ROW), have also been provided in the report.
For an in-depth understanding of the market, profiles of market participants are also part of this report. This report also discusses driving and restraining factors and key trends in the biobanking market.
This research covers biobanks dealing with basic science and clinical research. Forensic science, paternity testing, cryopreservation facilities or screening disease testing for newborns and fertility clinics dealing with ovum, sperm and embryo biobanks are not covered in this report. Transplantation and graft-related biobanks dealing with heart valves, cornea and cartilage/tendon are also not covered. Tissue banks for orthopedic, spine, dental, maxillofacial surgery and stem cells biobank for regenerative medicine are also not covered in this report.
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Synopsis
| Report Metrics | Details |
| Base year considered | 2020 |
| Forecast period considered | 2021-2026 |
| Base year market size | $58.5 billion |
| Market size forecast | $76.1 billion |
| Growth rate | CAGR of 4.5% from 2021 to 2026 |
| Units considered | $ Millions |
| Segments covered | Sample Type, Application, Ownership Type |
| Regions covered | North America, Europe, Asia-Pacific, Rest of the World (RoW) |
| Countries covered | U.S., Canada, Germany, France, U.K., Italy, Sweden, Spain, Switzerland, Denmark, Norway, Poland, Belgium, Austria, Netherlands, Russia, Japan, China, Australia, South Korea, India, New Zealand, Taiwan, Singapore, Malaysia, Thailand, Philippines, Indonesia, Latin America, Middle East and Africa |
| Key Market Drivers |
|
| Companies studied |
|
Report Highlights
The global market for biobanking technologies was valued at $186.3 billion in 2015. This market is expected to increase from $198.2 billion in 2016 to $240.2 billion in 2021 at a compound annual growth rate (CAGR) of 3.9% for 2016-2021.
Report Includes
- An overview of the global markets for biobanking, the storage of biological samples for the future.
- Analyses of global market trends, with data from 2015, estimates for 2016 and projections of compound annual growth rates (CAGRs) through 2021.
- Detailed analyses of how biobanks can lead to new products for specific diseases to overall industry trends.
- Breakdowns of the biobanking market by product, disease category, and geographic region or country.
- New products approved by the FDA, and those products expected to be approved within the forecast period.
- Analysis of the leading competitors, as well as emerging companies in the current worldwide biobanking market.
- Profiles of the manufacturers of leading products, and their specific product strategies are outlined.
Report Highlights
The global biobanking market was $141 billion in 2010 and is projected to increase by 30% between 2010 and 2015, at a compound annual growth rate (CAGR) of 5.4%.